Bryce D. Carmine
Chairman at KAZIA THERAPEUTICS LIMITED
Net worth: 43 716 $ as of 2023-11-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| David Ricks | M | 56 | 28 years | |
| John Friend | M | 54 | 3 years | |
| Steven Coffey | M | 63 | 12 years | |
| Ebru Davidson | F | - | 1 years | |
| Anat Ashkenazi | F | 51 | 23 years | |
| Jon Fyrwald | M | 63 | 19 years | |
| Alonzo Weems | M | - | 27 years | |
| Katherine Baicker | M | 52 | 13 years | |
| Travis Coy | M | 43 | 21 years | |
| Ralph Alvarez | M | 68 | 15 years | |
| Rosanne Dunn | M | - |
HaemaLogiX Pty Ltd.
 HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | - |
| Damian Clarke-Bruce | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 1 years |
| Edgardo Hernandez | M | - | 19 years | |
| Patrik Jonsson | M | 57 | 34 years | |
| Robert F. Apple | M | 58 | - | |
| John Cullity | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 9 years |
| Anna Sandham | F | - | 1 years | |
| Alan Liddle | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 11 years |
| Karen R. Krumeich | F | 70 | 2 years | |
| Geoffrey Nichol | M | 69 |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 2 years |
| Robert J. Heine | M | - | 16 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Graham Edmund Kelly | M | - | 21 years | |
| Iain Ross | M | 71 | 8 years | |
| Ronak H. Shah | M | - | 3 years | |
| Randall L. Tobias | M | - | 12 years | |
| John Paul O'Connor | M | 75 | 5 years | |
| Ellen Marram | F | 77 | 17 years | |
| Susan Mahony | M | 59 | 18 years | |
| Cristyn Humphreys | F | - | - | |
| Rolf K. Hoffmann | M | 64 | 17 years | |
| Alex Michael Azar | M | 56 | 4 years | |
| Pedro Granadillo | M | 77 | 34 years | |
| Frank M. Deane | M | 74 | 26 years | |
| Richard Pilnik | M | 67 | 25 years | |
| James Garner | M | - | 7 years | |
| Shah Hussain | M | 59 |
Eli Lilly Australia Pty Ltd.
 Eli Lilly Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Eli Lilly Australia Pty Ltd. manufactures and supplies pharmaceutical products. It develops medicines for diabetes, cancer, immunology, and pain. The company was founded in 1960 and is headquartered in West Ryde, Australia. | - |
| KULDEEP NEOTE | M | - | 17 years | |
| Jeffrey A. Winton | M | - | 3 years | |
| Diana McKenzie | F | 59 | 12 years | |
| Michael Harrington | M | 61 | 29 years | |
| Peter Gunning | M | - | 2 years | |
| Ian M. Phillips | M | - | 2 years | |
| Aarti Shah | M | 60 | 27 years | |
| Michael Ackermann | M | - | 2 years | |
| Gordon Hirsch | M | - | 1 years | |
| Gregory Davis | M | 70 | 20 years | |
| Gabrielle Heaton | F | - | 5 years | |
| Jan Lundberg | M | 70 | 8 years | |
| Anne Nobles | M | 67 | 22 years | |
| R. Hoover | M | 77 | 9 years | |
| Jeffrey Henderson | M | 59 | 7 years | |
| Karen N. Horn | M | 80 | 29 years | |
| Deirdre Connelly | F | 63 | 26 years | |
| Kathi P. Seifert | F | 74 | 26 years | |
| Melissa Barnes | F | 55 | 27 years | |
| Robert A. Armitage | M | 75 | 13 years | |
| Franklyn Prendergast | M | 79 | 22 years | |
| Michael Eskew | M | 74 | - | |
| Derica Rice | M | 59 | 14 years | |
| Keith E. Brauer | M | 75 | 6 years | |
| Alfred G. Gilman | M | 82 | - | |
| Marvin White | M | 61 | - | |
| Douglas Oberhelman | M | 71 | 7 years | |
| James Cornelius | M | 81 | 12 years | |
| Win Bischoff | M | 81 | 14 years | |
| Martin Feldstein | M | 84 | 10 years | |
| Webster Dunbar | M | 62 | 5 years | |
| Michael R. Meadows | M | - | 35 years | |
| Elaine Sullivan | M | 63 | 3 years | |
| Gregory D. Plowman | M | - | - | |
| Aaron L. Schacht | M | 56 | 10 years | |
| James Wooldridge | M | 58 | - | |
| Arnold Hanish | M | 76 | 28 years | |
| Brian Stuglik | M | 64 | 6 years | |
| Lucas Montarce | M | 47 | - | |
| Fadi Debes | M | - | - | |
| Owen Wallace | M | 55 | 11 years | |
| Allen Melemed | M | 60 | 22 years | |
| Michael Andriole | M | 51 | 16 years | |
| Juan Andres | M | 59 | 22 years | |
| Chuan Shih | M | - | - | |
| A. Jay Graf | M | - | 14 years | |
| Dominick Colangelo | M | 60 | - | |
| Stephen W. Kaldor | M | 62 | 12 years | |
| Patricia Martin | F | 63 | 26 years | |
| William Chin | M | 76 | - | |
| Ron D. Henriksen | M | 85 | 23 years | |
| Jerome H. Fleisch | M | - | 27 years | |
| Randall B. Riggs | M | 57 | - | |
| David Mullarkey | M | 57 | - | |
| Kimberly Marie Lein-Mathisen | F | 52 | 12 years | |
| Johanna Carmel Egan | M | - | - | |
| Jacques Tapiero | M | 66 | 31 years | |
| Robert Baughman | M | - | - | |
| Vincent P. Mihalik | M | 73 | - | |
| Enrique Conterno | M | 57 | 27 years | |
| W. Darin Moody | M | - | - | |
| Howard Levy | M | 70 | - | |
| Guido Neels | M | 75 | 12 years | |
| Joe C. Cook | M | 82 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 80 | 80.00% |
| Australia | 21 | 21.00% |
| Japan | 0 | -.--% |
| New Zealand | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Bryce D. Carmine
- Personal Network
